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INTERLEEK-I (IL-1) is a key mediator of cartilage matrix
degradation in osteoarthritis and rheumatoid arthritis. It
was found that the IL-l-induced suppression of
glycosaminoglycan (GAG) synthesis in rat articular carti-
lage occurred simultaneously with the accumulation of
nitrite (a metaboHte of nitric oxide (NO) in aqueous mi-
lieu) in the culture medium. NO-synthase inhibitors, L-
NMMA and L-NIO, inhibited both these IL-1 effects.
Dexamethasone suppressed GAG synthesis additively to
IL-1, but did not alter nitrite accumulation. Three NO-
donors (GEA 3175, SNAP and SIN-l) also had an inhibi-
tory effect on cartilage GAG synthesis. Therefore, it is
concluded that IL-1 induced suppression ofGAG synthe-
sis in rat articular cartilage is mediated by the production
of NO.
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Introduction
Loss of matrix proteoglycans from articular carti-
lage is one of the key events in the early stages of
destructive joint diseases such as osteoarthritis (OA)
and rheumatoid arthritis (RA). This leads to de-
creased resistance of articular cartilage against
compressive load, which is followed by develop-
ment of fissures and progressive destruction of ar-
ticular cartilage. Interleukin-1 (IL-1) is a cytokine
known to decrease proteoglycan synthesis in articu-
lar cartilage. 1-3 IL-1 also stimulates the synthesis of
major cartilage degrading enzymes, collagenase and
stromelysin, in chondrocytes and synovial cells.-5
Recent reports show that nitric oxide (NO) synthe-
sis is increased in arthritic joints.
-1 NO is synthesized
from the amino acid L-arginine in a reaction catalysed
by two distinct enzymes; constitutive NO synthase
(eNOS) releases small amounts of NO in response to
physiological stimuli while inducible NO synthase
(iNOS) produces higher amounts of NO when ex-
pressed by certain cytokines or bacterial products [for
reviews, see References 11-14]. IL-1 induces the
synthesis of NO in several cell types including
chondrocytes of articular cartilage.
15q9 Recent reports
have identified NO as a mediator of certain cytotoxic
effects of IL-1 on pancreatic [ cells and ovary. 2’21 The
actions ofNO in articular cartilage destruction are not
known, but the anti-proliferative effects on
chondrocytes in a co-culture with activated
995 Rapid Communications of Oxford Ltd
lymphocytes are attributed to the production of NO. 18
Of interest to rheumatologists is the growing evi-
dence implicating NO in inflammation, immune
regulation and autoimmunity. 22,23 However, the
pathophysiological role of this locally synthesized
NO in OA and RA is not known. The present study
was designed to test the hypothesis that NO is
involved in the IL-1 induced inhibition of
glycosaminoglycan (GAG) synthesis in articular car-
tilage. The present results show that NO acts as a
mediator of the IL-1 induced inhibition of GAG
synthesis in rat articular cartilage. A preliminary ac-
count of this work has been published previously.
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Materials and Methods
Animals: Twelve-week-old male Wistar rats were
used.
Reagentsand medium: IL-I[ (Immugenex, Los Ange-
les, USA), 3-morpholino-sydnonimine (SIN-l),
S-nitroso-N-acetyl-penicillamine (SNAP) and a novel
3-aryl-substituted oxatriazol derivate GEA 317525-27
(GEA Ltd, Copenhagen, Denmark), N-monomethyl-L-
arginine (L-NMMA) (Clinalfa, Liufelfingen, Switzer-
land), t-N-iminoethyl-ornithine (L-NIO) (Alexis Corp.,
Ltufelfingen, Switzerland), dexamethasone, (Orion
Pharmaceuticals, Helsinki, Finland), [35S]-sodium
sulphate (Du Pont, NEN Research Products, Boston,
MA, USA), Hanks’ balanced salt solution (GIBCO,
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Grand Island, NY, USA), L-arginine (Sigma, St Louis,
USA) and Lumasolve (Lumac, Basel, Switzerland)
were used. RPMI 1640 (GIBCO, Grand Island, NY,
USA) containing 10% heat-inactivated (56C, 30 min)
foetal bovine serum, antibiotics (100 U/ml penicillin,
100 btg/ml streptomycin and 250 ng/ml Fungizone)
was used as the culture medium.
Articular cartilage: Culture of rat femoral head car-
tilage was performed according to the modified
method of van den Berg et al. 28 Briefly, the femoral
heads were removed aseptically and incubated at
37C in a humidified 5% carbon dioxide atmosphere
for 24 h. At the beginning of incubation IL-1 and/or
drugs were added. After 12 h incubation equivalent
concentrations of NO-donors or NO synthase inhibi-
tors were added.
GAG synthesis: GAG synthesis in articular cartilage
was measured by the incorporation of p5S]-sulphate
into the cartilage as described.
28 [35S]-sodium sulphate
(1 btM) was added to the culture medium and after
24 h incubation, the femoral heads were washed,
fixed in ethanol and decalcified in 5% formic acid.
After decalcification bone was punched out and
articular cartilage digested in Lumasolve at 60C. The
amount of incorporated radioactivity was assayed by
using a liquid scintillation counter. After the bony
part of the femoral head had been removed, the
samples were weighed. The average weight of sam-
ples was 17.13 _+ 0.19 mg (mean _+ S.E.M.) (n 60).
Nitrite assay: The incubation medium was collected
after the incubation period of 24 h. Nitrite (NO2-) a
stable product of NO in aqueous solutions,29 was
used as an indicator of nitric oxide.
Results
IL-1 (0.3-30 ng/ml) decreased the cartilage GAG
synthesis in a dose-dependent manner (Fig. 1). Si-
multaneous accumulation of nitrite in the culture
medium was observed and the linear correlation
coefficient between GAG synthesis and nitrite con-
centration was -0.63 (p < 0.001, n 24). Non-stimu-
lated cartilage samples did not release measurable
concentrations of nitrite.
To assure the association of NO synthesis with the
inhibitory effects of IL-1 on GAG synthesis, the ef-
fects of two competitive inhibitors of NO synthesis
were studied. At concentrations needed to achieve a
major inhibition of nitrite accumulation, L-NMMA
(1000 ltiM) and t-NIO (50 btM) themselves caused a
16% and 17% reduction in GAG synthesis, t-NMMA
and t-NIO diminished both IL-1 (3 ng/ml)-induced
nitrite accumulation and inhibition of GAG synthesis
(Fig. 2). IL-1 alone caused 33% inhibition of GAG
synthesis. In the presence of t-NMMA (1000 btM) the
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FIG. 1. The dose-dependent effects of IL-1 on articular cartilage GAG
synthesis (black bars) and nitrite accumulation in the culture medium
(shaded bars). Articular cartilage samples were incubated for 24 h in the
presence of IL-1 (0.3-30 ng/ml). GAG and NO2- synthesis were determined
by [asS] sulphate incorporation and Griess reaction, respectively. Results
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FIG. 2. The effects of IL-1 (3 ng/ml) on articular cartilage GAG synthesis
(black bars) and nitrite accumulation (shaded bars) in the presence or
absence of two competitive inhibitors of NO synthesis. Panel A, L-NMMA
(1000 t.tM). Panel B, L-NIO (50 t.tM). GAG and NO2- synthesis were deter-
mined by [asS] sulphate incorporation and by Griess reaction after an
incubation period of 24 h. Results are expressed as the mean + S.E.M.
(n= 6).
ing inhibitory effect of IL-1 in the presence of t-NIO
(50 btM) was 6%. When t-NMMA or t-NIO were added
with IL-1 into the organ culture, the nitrite levels in
the medium were <1 btM and 1.7 l.tM after 24 h
incubation, respectively.










FIG. 3. The effect of IL-1 (3 ng/ml) on articular cartilage GAG synthesis
(black bars) and nitrite accumulation (shaded bars) in the culture medium
in the presence or absence of dexamethasone (Dexa, 1.0 l.tM). GAG and
NO- synthesis were determined by [asS] sulphate incorporation and Griess
reaction after an incubation period of 24 h. Results are expressed as the
mean + S.E.M. (n 6).
Addition of t-arginine (30-1000 M), the substrate
of NO synthesis, could not induce NO synthesis
alone, but suppressed nitrite accumulation dose-
dependently in the presence of IL-1 (1 ng/ml) into
the culture medium. At high concentrations, t-
arginine (>30 l.tM) alone inhibited GAG synthesis as
did t-NMMA and t-NIO (data not shown).
Dexamethasone was an inhibitor of GAG
biosynthesis, as evidenced by 1.0 btM drug concen-
tration which had a negative impact of 16% on GAG
synthesis. When combined with IL-1 (3 ng/ml),
dexamethasone had an additive inhibitory effect on
GAG synthesis (Fig. 3). Dexamethasone did not alter
IL-1 induced production of NO in intact articular
cartilage. Neither could it alone induce any measur-
able nitrite accumulation. These findings were con-
firmed by a similar procedure using ten-fold higher
concentrations of dexamethasone (10 l.tM) (data not
shown).
The effects of three NO-releasing compounds, SIN-
1, SNAP and a novel oxatriazole derivative GEA 3175,
on GAG synthesis were studied. A concentration-
dependent inhibition was caused by each of the
three compounds in the order of potency GEA 3175
>SNAP > SIN-1. The inhibitory effect plateaued at
24-33% inhibition (Fig. 4).
Discussion
IL-1 is a well-established mediator of inflammation
and cartilage destruction in both OA and RA. 5,1
Within the cartilage IL-1 is known to promote carti-
lage destruction by inducing the synthesis of the
major cartilage matrix degrading proteases,
stromelysin and collagenase.-5 In addition, the in-
hibitory effect of IL-1 on the synthesis of new GAGs
is well documented1-,2, and the treatment of experi-
mental arthritis with anti-IL-1 antibodies could sig-
nificantly suppress inflammation, decrease the en-
hanced cartilage breakdown and normalize
chondrocyte synthetic function.-6 Our findings
concerning IL-1 induced inhibition of the GAG
biosynthesis are well in keeping with those of earlier
studies,2 even thodgh the most recent studies2,7
measure almost twice as large an inhibition of GAG
synthesis as was found in this study. This difference
is probably due to methodological differences be-
tween the studies. In the present work the
radiolabelled sulphate was added to the culture con-
comitantly with IL-1 whereas in most of the recent
studies it was added after the 6-12 h lag period
needed to achieve the inhibitory action of IL-1 on
GAG synthesis.2,7
In its target cells IL-1 binds to specific cell surface
receptors and the expression and suppression of a
wide range of genes takes place.8 Even though the
biological effects of IL-1 on GAG synthesis in articu-
lar cartilage tre well known, the second messenger
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FIG. 4. The dose-dependent inhibitory effect of exogenous NO in the form of NO-releasing compounds GEA 3175, SNAP and SIN-1 on GAG synthesis
in rat articular cartilage. GAG synthesis was determined by [asS] sulphate incorporation after an incubation period of 24 h. Results are expressed as the
mean + S.E.M. (n 6-10).
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Induction of iNOS by IL-1 has been shown to take
place in certain cell types, including human articular
chondrocytes. 15,16,19 Increased concentrations of the
NO catabolite nitrite have been found in synovial
fluid and sera of patients with OA or RA. Four
groups have recently demonstrated that increased
production of NO is associated with experimental
arthritis, and the administration of inhibitors of NOS
suppress the reaction.>m The cellular actions of NO
on articular cartilage are not known. Recently, Kondo
et al. showed that NO has an antiproliferative effect
on isolated chondrocytes in a co-culture with acti-
vated lymphocytes.
8
The production of NO by iNOS leads to inhibition
of several important steps of the cellular metabolism,
specifically aerobic energy metabolism, DNA replica-
tion and protein synthesis in other cell types, such as
macrophages, hepatocytes, lymphocytes and tumour
cells.39-43 Recently, NO has been identified as the
mediator of IL-1 induced cytotoxic effects towards
pancreatic [ cells and ovary cells.2,21 The present
results give several arguments to support the hypo-
thesis that the inhibition of GAG biosynthesis in
response to IL-1 is mediated by the generation ofNO
in the articular cartilage. First, in IL-1 stimulated
articular cartilage we observed a strong association
between NO production and inhibition of GAG syn-
thesis. Secondly, when exogenous NO in the form of
NO-releasing compounds (SIN-l, SNAP and GEA
3175) was added to the culture, an inhibition ofGAG
synthesis was seen. The two compounds with
mesoinic structures, i.e. the sydnonimine SIN-1 and
the recently developed oxatriazole-imine derivative
GEA 317525-27 as well as the nitrosothiol SNAP release
NO in aqueous solutions without a need of cofactors
or enzymatic conversion.44 SIN-1 releases superoxide
anion (O2-) in addition to NO. These radicals can
react to form peroxynitrite (ONOO-) which may
explain the differences in the potency of SIN-1 and
compounds that release NO only.44’45 The order of
potency of these three NO-donors in the present
study was similar to that shown in leukocytes and
platelets.2<’7 Thirdly, the two competitive inhibitors
of NO synthase, t-NMMA and t-NIO blocked IL-1
induced NO production, simultaneously preventing
the IL-1 induced inhibition of GAG synthesis. The
present findings accord well with those reported by
Taskiran et al. 37 during the processing of this manu-
script.
The NO production in rat articular cartilage in
response to IL-1 was decreased after supplementa-
tion of medium with higher concentrations of L-
arginine. This phenomenon has earlier been re-
corded in lapine articular chondrocytes, suggesting a
rather high affinity of the chondrocyte NOS for the
endogenous t-arginine. 15 In our study t-arginine
alone, as well as t-NMMA and t-NIO, suppressed
GAG synthesis thus giving additional data to the
earlier suggestions of undefined toxic effects of
higher concentrations of t-arginine on the articular
chondrocytes5 and -arginine analogue inhibitors of
NOS on other tissues.
12
A number of isolforms of iNOS have been de-
scribed. 14 The expression of the iNOS is inhibited by
glucocorticoids in several cell types, such as
macrophages and endothelial cells. 11-14 In articular
cartilage, IL-1 induced production of NO was not
altered by dexamethasone, confirming similar obser-
vations in human and rabbit chondrocytes. 1<17 Be-
sides, dexamethasone had an inhibitory effect on
GAG synthesis, which was additive to that of IL-1.
The clinical and subjective improvement of the RA
and OA patients after glucocorticoid treatment is
thought to be mediated by the inhibitory action of
glucocorticoids on the synthesis of proinflammatory
cytokines, prostaglandins and proteolytic en-
zymes.449 The present findings of the additive sup-
pressive effects of dexamethasone and IL-1 on GAG
synthesis and the failure of dexamethasone to pre-
vent the induction of NO synthesis in articular carti-
lage could be regarded as unfavourable events in the
pathogenesis of cartilage destruction. Furthermore,
these findings support the assumption of Stefanovic-
Racic et al. 23 that the insensitivity of iNOS to
glucocorticoids in articular cartilage might partly
explain why anti-inflammatory steroids fail to retard
the cartilage destruction in arthritic joints even
though they suppress the inflammatory action.
In conclusion, these observations suggest that the
effects of IL-1 and glucocorticoids on rat articular
cartilage GAG biosynthesis are mediated by different
intracellular mechanisms, which in the case of IL-1
seems to be NO.
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